Craig Bennett

Dr. Craig Bennett

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CBCraig Bennett
Craig Bennett
JCJacinda Christie
Jacinda Christie
FRFred Ramsdell
Fred Ramsdell
MBMary E. Brunkow
Mary E. Brunkow
PFPolly J. Ferguson
Polly J. Ferguson
HOHans D. Ochs
Hans D. Ochs

1 July 2004 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MPMelissa A. Parisi
Melissa A. Parisi
CBCraig Bennett
Craig Bennett
MEMelissa L. Eckert
Melissa L. Eckert
WDWilliam B. Dobyns
William B. Dobyns
JGJoseph G. Gleeson
Joseph G. Gleeson
IGIan A. Glass
Ian A. Glass

1 August 2001 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
CBCraig Bennett
Craig Bennett
MBMary E. Brunkow
Mary E. Brunkow
FRFred Ramsdell
Fred Ramsdell
KOKathy C. O'Briant
Kathy C. O'Briant
QZQili Zhu
Qili Zhu
PCPhillip F. Chance
Phillip F. Chance

1 December 2001 in Current Opinion in Pediatrics
Verified
Journal Article
Closed access
CBCraig Bennett
Craig Bennett
HOHans D. Ochs
Hans D. Ochs
The rare syndrome known as IPEX (OMIM: 304930) is characterized by immune-dysfunction, polyendocrinopathy, enteropathy, and X-linked inheritance. The gene responsible for IPEX maps to Xp11.23-q13.3, a region of the X chromosome that also harbors the Wiskott-Aldrich syndrome gene (WASP). IPEX syndrome results from mutations of a unique DNA binding protein gene, FOXP3. Mutations invariably impair the seemingly essential forkhead domain of the protein, which is uniquely located in the carboxyl terminus, affecting protein function. In this review, we describe the identification of IPEX as a unique X-linked syndrome, the clinical features of IPEX, mutations of the immune-specific FOXP3 DNA binding protein, and bone marrow transplantation as a potential cure for the syndrome, which is usually lethal within the first year of life in affected males.

14 January 2003 in Neurology
Verified
Journal Article
Closed access
PDF file
VSV. A. Street
V. A. Street
CBCraig Bennett
Craig Bennett
JGJ. D. Goldy
J. D. Goldy
ASA. J. Shirk
A. J. Shirk
KKK. A. Kleopa
K. A. Kleopa
PCP. F. Chance
P. F. Chance
Background: Charcot-Marie-Tooth (CMT) neuropathy is a heterogeneous group of inherited disorders of the peripheral nervous system. The authors recently mapped an autosomal dominant demyelinating form of CMT type 1 (CMT1C) to chromosome 16p13.1-p12.3. Objective: To find the gene mutations underlying CMT1C. Methods: The authors used a combination of standard positional cloning and candidate gene approaches to identify the causal gene for CMT1C. Western blot analysis was used to determine relative protein levels in patient and control lymphocyte extracts. Northern blotting was used to characterize gene expression in 1) multiple tissues; 2) developing sciatic nerve; and 3) nerve-crush and nerve-transection experiments. Results: The authors identified missense mutations (G112S, T115N, W116G) in the LITAFgene (lipopolysaccharide-induced tumor necrosis factor-α factor) in three CMT1C pedigrees. LITAF, which is also referred to as SIMPLE, is a widely expressed gene encoding a 161-amino acid protein that may play a role in protein degradation pathways. The mutations associated with CMT1C were found to cluster, defining a domain of the LITAF protein having a critical role in peripheral nerve function. Western blot analysis suggested that the T115N and W116G mutations do not alter the level of LITAF protein in peripheral blood lymphocytes. The LITAF transcript is expressed in sciatic nerve, but its level of expression is not altered during development or in response to nerve injury. This finding is in stark contrast to that seen for other known genes that cause CMT1. Conclusions: Mutations in LITAF may account for a significant proportion of CMT1 patients with previously unknown molecular diagnosis and may define a new mechanism of peripheral nerve perturbation leading to demyelinating neuropathy.

9 September 2005 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
MPM A Parisi
M A Parisi
DDD Doherty
D Doherty
MEM L Eckert
M L Eckert
DSD W W Shaw
D W W Shaw
HOH Ozyurek
H Ozyurek
IGI A Glass
I A Glass
Background: Joubert syndrome (JS) is an autosomal recessive disorder characterised by hypotonia, ataxia, mental retardation, altered respiratory pattern, abnormal eye movements, and a brain malformation known as the molar tooth sign (MTS) on cranial MRI. Four genetic loci have been mapped, with two genes identified (AHI1 and NPHP1). Methods: We screened a cohort of 117 JS subjects for AHI1 mutations by a combination of haplotype analysis and sequencing of the gene, and for the homozygous NPHP1 deletion by sequencing and marker analysis. Results: We identified a total of 15 novel AHI1 mutations in 13 families, including nonsense, missense, splice site, and insertion mutations, with some clustering in the WD40 domains. Eight families were consanguineous, but no single founder mutation was apparent. In addition to the MTS, retinal dystrophy was present in 11 of 12 informative families; however, no subjects exhibited variable features of JS such as polydactyly, encephalocele, colobomas, or liver fibrosis. In contrast to previous reports, we identified two families with affected siblings who developed renal disease consistent with nephronophthisis (NPH) in their 20s. In addition, two individuals with classic NPH were found to have homozygous NPHP1 deletions. Conclusions: Overall, 11% of subjects had AHI1 mutations, while ∼2% had the NPHP1 deletion, representing a total of less than 15% in a large JS cohort. Some preliminary genotype-phenotype correlations are possible, notably the association of renal impairment, specifically NPH, in those with NPHP1 deletions. Subjects with AHI1 mutations may be at risk of developing both retinal dystrophy and progressive kidney disease.